SlideShare a Scribd company logo
Assignment – 01
Pharmacogentics-Genomics in
relation to molecular Diagnosis -
Molecular Therapeutic technologies
By
Narra Naga Pavan Kumar (KVPY Fellow)
1st M.Tech Biotech (14IS1D0301)
Institute of Science & Technology, JNTUK University
Interrelation between the pharmacogenomics
and Genetics
• Both are nearly same but the study range is variying
• Pharmacogenomics is the branch of pharmacology that involves the
study of drug response with the entire compliment of genes.
• Pharmacogenetics, refers to study of drug response with a relatively
restricted number of genes.
Pharmacogenomics - Genetics
• genome-wide approaches
• more than 1,000,000
polymorphisms
• Study of polymorphisms
• Example :- next generation
Sequenceing
• Gene wide approach
• More then 25, 000 genes
• Study of mutations
• Example :- Microarrays
Why the study is needed
• Due the genomic variation
• Due to the environmental factors - Ecogenetics
• Example :- ethanol sensitivity, which is related to acetaldehyde-
dehydrogenase deficiency.
• Due the food we are taking
• Example :- milk intolerance because of lactase deficiency.
• The immune responses of a person
• Toxicogenetics :- Example :- carcinogens
•Results = personalised medicine
Molecular Therapeutic technologies
Personalised medicine
• Personalized medicine is a broad health care that is informed by each
person’s unique clinical, genetic, genomic, and environmental
information to individualizing patient care across the continuum
(from health to disease).
• Goal :- to optimize medical care and outcomes for each individual, to
include treatments, medication types and dosages, and/or prevention
strategies may differ from person to person
Therapeutic principles
• All drug effects vary from person to person and all drug effects are influenced by
genes.
• Most drug responses are multifactorial (that is, many genes and many
environmental factors contribute to them).
• Genetic polymorphisms of single genes, including mutations in coding sequences,
gene duplications, gene deletions and regulatory mutations affect numerous drug-
metabolizing enzymes. Several cytochrome-P450 enzymes (for example, CYP2D6
and CYP2C9), N-acetyltransferases (NAT2), thiopurine methyltransferase (TPMT)
and UDPglucuronosyltransferases (UDP-GT) are examples. Individuals that possess
these polymorphisms are at risk of experiencing documented adverse reactions or
inefficacy of drugs at usual doses.
• Genetic polymorphisms of drug targets and drug transporters are increasingly
recognized (receptors, ion channels, growth factors) as causing variation in drug
responses.
• Several targets of cancer therapy, for example, the epidermal-growth-factor
receptor, respond to treatment only in subgroups of patients who carry sensitizing
mutations of these targets.
• The frequency of variation of drug effects,whether multifactorial or genetic,
varies considerably in ethnically defined populations (for example, alleles of N-
acetyltransferases).
• Application of response-predictive genetic profiles (for example, genotyping for
polymorphisms in antidepressant or cancer-drug therapy) on clinical outcomes
has, so far, been done mostly in academic centres and has not yet reached clinical
practice.
The main principle involved is
Genetic Polymorphisms in Drug Metabolism and
Disposition
• Genetic Polymorphisms in Drug Targets
• Genetic Polymorphisms in Drug Transporters
Example :- selection and dosing of chemotherapy
for a patient with acute lymphoblastic leukemia
(ALL)
• Genetic polymorphisms in drug-metabolizing enzymes can have a profound effect
on toxicity and efficacy of medications used to treat ALL and that individualizing
drug dosages can improve clinical outcome.
• It has also been established that the genotype of leukemic lymphoblasts is an
important prognostic variable that can be used to guide the intensity of
treatment.
• all these will be placed on a chip called ALL Chip give the results for a selective
therapy. (reference William E. Evans, et al Science 286, 487, 1999) as same as
microarray technology.
Examples for the drug metabolism
Molecular Diagnosis
Diagnosis
• Next generation sequencing.
• DNA chip.
• Transcriptome profiling.
References:-
• Genomic and personalized medicine: foundations and applications GEOFFREY S.
GINSBURG et al., Translational Research December 2009;272 – 287.
• Molecular Genetic Markers as A Basis for Personalized Medicine Sonja Pavlovi et
al., J Med Biochem 33: 8–21, 2014.
• Pharmacogenetics: data, concepts and tools to improve drug discovery and drug
treatment Jürgen Brockmöller et al., Eur J Clin Pharmacol (2008) 64:133–157.
• Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
William E. Evans, et al. Science 286, 487 (1999).
• Pharmacogenetics – five decades of therapeutic lessons from genetic diversity,
Urs A.Meyer, Nature Reviews Genetics September 2004, vol 4, 669 -676

More Related Content

What's hot

What's hot (20)

Personalized Medicine Overview
Personalized Medicine OverviewPersonalized Medicine Overview
Personalized Medicine Overview
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Pharmacogenetics and individual variation of drug response
Pharmacogenetics and individual variation of drug responsePharmacogenetics and individual variation of drug response
Pharmacogenetics and individual variation of drug response
 
Benefits of pharmacogenomics
Benefits of pharmacogenomicsBenefits of pharmacogenomics
Benefits of pharmacogenomics
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
personalized medicine
personalized medicinepersonalized medicine
personalized medicine
 
Personalized medicines
Personalized medicinesPersonalized medicines
Personalized medicines
 
Personalized medicines
Personalized medicinesPersonalized medicines
Personalized medicines
 
Targeted drug dilivary ppt 2nd sem
Targeted drug dilivary ppt 2nd semTargeted drug dilivary ppt 2nd sem
Targeted drug dilivary ppt 2nd sem
 
POST brochure
POST brochurePOST brochure
POST brochure
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
 
Genomics and proteomics
Genomics and proteomicsGenomics and proteomics
Genomics and proteomics
 
Personalised Medicine
Personalised MedicinePersonalised Medicine
Personalised Medicine
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Personalized medicine in pediatric cancer
Personalized medicine in pediatric cancerPersonalized medicine in pediatric cancer
Personalized medicine in pediatric cancer
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Lipinski Jmrc Lecture1 Nov2008
Lipinski Jmrc Lecture1 Nov2008Lipinski Jmrc Lecture1 Nov2008
Lipinski Jmrc Lecture1 Nov2008
 
Personalized medicine ppt
Personalized medicine pptPersonalized medicine ppt
Personalized medicine ppt
 
Personalized medicine
Personalized medicinePersonalized medicine
Personalized medicine
 
Pharmacogenomics: The right drug to the right person.
Pharmacogenomics: The right drug to the right person.Pharmacogenomics: The right drug to the right person.
Pharmacogenomics: The right drug to the right person.
 

Viewers also liked

Laporan hp
Laporan hpLaporan hp
Laporan hp
njw21
 
values education 4
values education 4values education 4
values education 4
Jenie Juatco
 
Ajk terkini
Ajk terkiniAjk terkini
Ajk terkini
njw21
 

Viewers also liked (15)

Евгений Атанов. Осознанность - ключ к здоровью
Евгений Атанов. Осознанность - ключ к здоровьюЕвгений Атанов. Осознанность - ключ к здоровью
Евгений Атанов. Осознанность - ключ к здоровью
 
Happy father’s day
Happy father’s dayHappy father’s day
Happy father’s day
 
Pet 485 supervision presentation mike mc_kenzie
Pet 485 supervision presentation mike mc_kenziePet 485 supervision presentation mike mc_kenzie
Pet 485 supervision presentation mike mc_kenzie
 
Ajk
AjkAjk
Ajk
 
Laporan hp
Laporan hpLaporan hp
Laporan hp
 
Using EAC-CPF
Using EAC-CPFUsing EAC-CPF
Using EAC-CPF
 
values education 4
values education 4values education 4
values education 4
 
Contrucción de subjetividades
Contrucción de subjetividadesContrucción de subjetividades
Contrucción de subjetividades
 
LA AMISTAD
LA AMISTADLA AMISTAD
LA AMISTAD
 
Paula andrea álvarez vásquez
Paula andrea álvarez vásquezPaula andrea álvarez vásquez
Paula andrea álvarez vásquez
 
Portfolio
PortfolioPortfolio
Portfolio
 
Task 4 - Advertising Campaigns
Task 4  - Advertising CampaignsTask 4  - Advertising Campaigns
Task 4 - Advertising Campaigns
 
εμπλουτισμός σεναρίου
εμπλουτισμός σεναρίουεμπλουτισμός σεναρίου
εμπλουτισμός σεναρίου
 
Rsa -gauss jordan
Rsa -gauss jordanRsa -gauss jordan
Rsa -gauss jordan
 
Ajk terkini
Ajk terkiniAjk terkini
Ajk terkini
 

Similar to pharmocogenomics and genetics in relation with molecular therapeutics and diagnosis

DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptxDOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
SubhamRoy63
 

Similar to pharmocogenomics and genetics in relation with molecular therapeutics and diagnosis (20)

Gyan credit seminar 3 jun copy
Gyan credit seminar 3 jun   copyGyan credit seminar 3 jun   copy
Gyan credit seminar 3 jun copy
 
Pharmacogenomics, by kk sahu
Pharmacogenomics, by kk sahuPharmacogenomics, by kk sahu
Pharmacogenomics, by kk sahu
 
genetic polymorphism new Presentation.pptx
genetic polymorphism new Presentation.pptxgenetic polymorphism new Presentation.pptx
genetic polymorphism new Presentation.pptx
 
Precision Psychiatry .pptx
Precision Psychiatry .pptxPrecision Psychiatry .pptx
Precision Psychiatry .pptx
 
Pharmacological implications of genetic polymorphism and Pharmacogenetics
Pharmacological implications of genetic polymorphism and PharmacogeneticsPharmacological implications of genetic polymorphism and Pharmacogenetics
Pharmacological implications of genetic polymorphism and Pharmacogenetics
 
pharmacogenomics by vaiibhavi
pharmacogenomics by vaiibhavipharmacogenomics by vaiibhavi
pharmacogenomics by vaiibhavi
 
Pharmacogenomics.pptx
Pharmacogenomics.pptxPharmacogenomics.pptx
Pharmacogenomics.pptx
 
Pharmacogenomics-2014.ppt
Pharmacogenomics-2014.pptPharmacogenomics-2014.ppt
Pharmacogenomics-2014.ppt
 
pharmacogenomics
pharmacogenomicspharmacogenomics
pharmacogenomics
 
Chapter 19 pharmacogenomics
Chapter 19 pharmacogenomicsChapter 19 pharmacogenomics
Chapter 19 pharmacogenomics
 
Pharmacogenetics
PharmacogeneticsPharmacogenetics
Pharmacogenetics
 
DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptxDOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
 
Multi Omics Approach in Medicine
Multi Omics Approach in MedicineMulti Omics Approach in Medicine
Multi Omics Approach in Medicine
 
1. Pharmacogenomics.pptx
1. Pharmacogenomics.pptx1. Pharmacogenomics.pptx
1. Pharmacogenomics.pptx
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
Application of genomic in Pharmacogenomicsof new drug
Application of genomic in Pharmacogenomicsof new drugApplication of genomic in Pharmacogenomicsof new drug
Application of genomic in Pharmacogenomicsof new drug
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
pharmacogenomicspptnsu-191212202112 (1).pptx
pharmacogenomicspptnsu-191212202112 (1).pptxpharmacogenomicspptnsu-191212202112 (1).pptx
pharmacogenomicspptnsu-191212202112 (1).pptx
 
Pharmacogenetics and Pharmacogenomics
Pharmacogenetics and PharmacogenomicsPharmacogenetics and Pharmacogenomics
Pharmacogenetics and Pharmacogenomics
 
PHARMACOGENOMICS AND PRECISION MEDICINE
PHARMACOGENOMICS AND PRECISION MEDICINEPHARMACOGENOMICS AND PRECISION MEDICINE
PHARMACOGENOMICS AND PRECISION MEDICINE
 

Recently uploaded

Search and Society: Reimagining Information Access for Radical Futures
Search and Society: Reimagining Information Access for Radical FuturesSearch and Society: Reimagining Information Access for Radical Futures
Search and Society: Reimagining Information Access for Radical Futures
Bhaskar Mitra
 
Essentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with ParametersEssentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with Parameters
Safe Software
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Peter Udo Diehl
 

Recently uploaded (20)

Introduction to Open Source RAG and RAG Evaluation
Introduction to Open Source RAG and RAG EvaluationIntroduction to Open Source RAG and RAG Evaluation
Introduction to Open Source RAG and RAG Evaluation
 
PLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. StartupsPLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. Startups
 
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptxWSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
 
UiPath Test Automation using UiPath Test Suite series, part 1
UiPath Test Automation using UiPath Test Suite series, part 1UiPath Test Automation using UiPath Test Suite series, part 1
UiPath Test Automation using UiPath Test Suite series, part 1
 
Agentic RAG What it is its types applications and implementation.pdf
Agentic RAG What it is its types applications and implementation.pdfAgentic RAG What it is its types applications and implementation.pdf
Agentic RAG What it is its types applications and implementation.pdf
 
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
 
Mission to Decommission: Importance of Decommissioning Products to Increase E...
Mission to Decommission: Importance of Decommissioning Products to Increase E...Mission to Decommission: Importance of Decommissioning Products to Increase E...
Mission to Decommission: Importance of Decommissioning Products to Increase E...
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
 
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
Unsubscribed: Combat Subscription Fatigue With a Membership Mentality by Head...
 
Search and Society: Reimagining Information Access for Radical Futures
Search and Society: Reimagining Information Access for Radical FuturesSearch and Society: Reimagining Information Access for Radical Futures
Search and Society: Reimagining Information Access for Radical Futures
 
10 Differences between Sales Cloud and CPQ, Blanka Doktorová
10 Differences between Sales Cloud and CPQ, Blanka Doktorová10 Differences between Sales Cloud and CPQ, Blanka Doktorová
10 Differences between Sales Cloud and CPQ, Blanka Doktorová
 
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
 
IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024
 
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
From Daily Decisions to Bottom Line: Connecting Product Work to Revenue by VP...
 
To Graph or Not to Graph Knowledge Graph Architectures and LLMs
To Graph or Not to Graph Knowledge Graph Architectures and LLMsTo Graph or Not to Graph Knowledge Graph Architectures and LLMs
To Graph or Not to Graph Knowledge Graph Architectures and LLMs
 
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptxUnpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
 
Essentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with ParametersEssentials of Automations: Optimizing FME Workflows with Parameters
Essentials of Automations: Optimizing FME Workflows with Parameters
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
 
"Impact of front-end architecture on development cost", Viktor Turskyi
"Impact of front-end architecture on development cost", Viktor Turskyi"Impact of front-end architecture on development cost", Viktor Turskyi
"Impact of front-end architecture on development cost", Viktor Turskyi
 

pharmocogenomics and genetics in relation with molecular therapeutics and diagnosis

  • 1. Assignment – 01 Pharmacogentics-Genomics in relation to molecular Diagnosis - Molecular Therapeutic technologies By Narra Naga Pavan Kumar (KVPY Fellow) 1st M.Tech Biotech (14IS1D0301) Institute of Science & Technology, JNTUK University
  • 2.
  • 3. Interrelation between the pharmacogenomics and Genetics • Both are nearly same but the study range is variying • Pharmacogenomics is the branch of pharmacology that involves the study of drug response with the entire compliment of genes. • Pharmacogenetics, refers to study of drug response with a relatively restricted number of genes.
  • 4. Pharmacogenomics - Genetics • genome-wide approaches • more than 1,000,000 polymorphisms • Study of polymorphisms • Example :- next generation Sequenceing • Gene wide approach • More then 25, 000 genes • Study of mutations • Example :- Microarrays
  • 5. Why the study is needed • Due the genomic variation • Due to the environmental factors - Ecogenetics • Example :- ethanol sensitivity, which is related to acetaldehyde- dehydrogenase deficiency. • Due the food we are taking • Example :- milk intolerance because of lactase deficiency. • The immune responses of a person • Toxicogenetics :- Example :- carcinogens •Results = personalised medicine
  • 6.
  • 8. Personalised medicine • Personalized medicine is a broad health care that is informed by each person’s unique clinical, genetic, genomic, and environmental information to individualizing patient care across the continuum (from health to disease). • Goal :- to optimize medical care and outcomes for each individual, to include treatments, medication types and dosages, and/or prevention strategies may differ from person to person
  • 9. Therapeutic principles • All drug effects vary from person to person and all drug effects are influenced by genes. • Most drug responses are multifactorial (that is, many genes and many environmental factors contribute to them). • Genetic polymorphisms of single genes, including mutations in coding sequences, gene duplications, gene deletions and regulatory mutations affect numerous drug- metabolizing enzymes. Several cytochrome-P450 enzymes (for example, CYP2D6 and CYP2C9), N-acetyltransferases (NAT2), thiopurine methyltransferase (TPMT) and UDPglucuronosyltransferases (UDP-GT) are examples. Individuals that possess these polymorphisms are at risk of experiencing documented adverse reactions or inefficacy of drugs at usual doses.
  • 10. • Genetic polymorphisms of drug targets and drug transporters are increasingly recognized (receptors, ion channels, growth factors) as causing variation in drug responses. • Several targets of cancer therapy, for example, the epidermal-growth-factor receptor, respond to treatment only in subgroups of patients who carry sensitizing mutations of these targets. • The frequency of variation of drug effects,whether multifactorial or genetic, varies considerably in ethnically defined populations (for example, alleles of N- acetyltransferases). • Application of response-predictive genetic profiles (for example, genotyping for polymorphisms in antidepressant or cancer-drug therapy) on clinical outcomes has, so far, been done mostly in academic centres and has not yet reached clinical practice.
  • 11. The main principle involved is
  • 12. Genetic Polymorphisms in Drug Metabolism and Disposition • Genetic Polymorphisms in Drug Targets • Genetic Polymorphisms in Drug Transporters
  • 13. Example :- selection and dosing of chemotherapy for a patient with acute lymphoblastic leukemia (ALL) • Genetic polymorphisms in drug-metabolizing enzymes can have a profound effect on toxicity and efficacy of medications used to treat ALL and that individualizing drug dosages can improve clinical outcome. • It has also been established that the genotype of leukemic lymphoblasts is an important prognostic variable that can be used to guide the intensity of treatment. • all these will be placed on a chip called ALL Chip give the results for a selective therapy. (reference William E. Evans, et al Science 286, 487, 1999) as same as microarray technology.
  • 14. Examples for the drug metabolism
  • 16. Diagnosis • Next generation sequencing. • DNA chip. • Transcriptome profiling.
  • 17.
  • 18.
  • 19. References:- • Genomic and personalized medicine: foundations and applications GEOFFREY S. GINSBURG et al., Translational Research December 2009;272 – 287. • Molecular Genetic Markers as A Basis for Personalized Medicine Sonja Pavlovi et al., J Med Biochem 33: 8–21, 2014. • Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment Jürgen Brockmöller et al., Eur J Clin Pharmacol (2008) 64:133–157. • Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics William E. Evans, et al. Science 286, 487 (1999). • Pharmacogenetics – five decades of therapeutic lessons from genetic diversity, Urs A.Meyer, Nature Reviews Genetics September 2004, vol 4, 669 -676